Literature DB >> 16322264

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

Søren Skov1, Marianne Terndrup Pedersen, Lars Andresen, Per Thor Straten, Anders Woetmann, Niels Odum.   

Abstract

We show that histone deacetylase (HDAC) inhibitors lead to functional expression of MHC class I-related chain A and B (MICA/B) on cancer cells, making them potent targets for natural killer (NK) cell-mediated killing through a NK group 2, member D (NKG2D) restricted mechanism. Blocking either apoptosis or oxidative stress caused by HDAC inhibitor treatment did not affect MICA/B expression, suggesting involvement of a separate signal pathway not directly coupled to induction of cell death. HDAC inhibitor treatment induced glycogen synthase kinase-3 (GSK-3) activity and down-regulation of GSK-3 by small interfering RNA or by different inhibitors showed that GSK-3 activity is essential for the induced MICA/B expression. We thus present evidence that cancer cells which survive the direct induction of cell death by HDAC inhibitors become targets for NKG2D-expressing cells like NK cells, gammadelta T cells, and CD8 T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16322264     DOI: 10.1158/0008-5472.CAN-05-0599

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  100 in total

1.  Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Authors:  Susanne H Baumeister; Joana Murad; Lillian Werner; Heather Daley; Helene Trebeden-Negre; Joanina K Gicobi; Adam Schmucker; Jake Reder; Charles L Sentman; David E Gilham; Frédéric F Lehmann; Ilene Galinsky; Heidi DiPietro; Kristen Cummings; Nikhil C Munshi; Richard M Stone; Donna S Neuberg; Robert Soiffer; Glenn Dranoff; Jerome Ritz; Sarah Nikiforow
Journal:  Cancer Immunol Res       Date:  2018-11-05       Impact factor: 11.151

2.  Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins.

Authors:  Anders Woetmann; Paola Lovato; Karsten W Eriksen; Thorbjørn Krejsgaard; Tord Labuda; Qian Zhang; Anne-Merethe Mathiesen; Carsten Geisler; Arne Svejgaard; Mariusz A Wasik; Niels Ødum
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

3.  The histone deacetylase inhibitor valproic acid lessens NK cell action against oncolytic virus-infected glioblastoma cells by inhibition of STAT5/T-BET signaling and generation of gamma interferon.

Authors:  Christopher A Alvarez-Breckenridge; Jianhua Yu; Richard Price; Min Wei; Yan Wang; Michal O Nowicki; Yoonhee P Ha; Stephen Bergin; Christine Hwang; Soledad A Fernandez; Balveen Kaur; Michael A Caligiuri; E Antonio Chiocca
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

Review 4.  Functions of NKG2D in CD8+ T cells: an opportunity for immunotherapy.

Authors:  Kushal Prajapati; Cynthia Perez; Lourdes Beatriz Plaza Rojas; Brianna Burke; Jose A Guevara-Patino
Journal:  Cell Mol Immunol       Date:  2018-02-05       Impact factor: 11.530

Review 5.  Therapeutic approaches to enhance natural killer cell cytotoxicity against cancer: the force awakens.

Authors:  Richard W Childs; Mattias Carlsten
Journal:  Nat Rev Drug Discov       Date:  2015-05-22       Impact factor: 84.694

6.  Sirt1 promotes axonogenesis by deacetylation of Akt and inactivation of GSK3.

Authors:  Xiao-Hong Li; Chong Chen; Yue Tu; Hong-Tao Sun; Ming-Liang Zhao; Shi-Xiang Cheng; Yang Qu; Sai Zhang
Journal:  Mol Neurobiol       Date:  2013-03-10       Impact factor: 5.590

7.  Histone deacetylase inhibitor sensitizes apoptosis-resistant melanomas to cytotoxic human T lymphocytes through regulation of TRAIL/DR5 pathway.

Authors:  Ali R Jazirehi; Siavash K Kurdistani; James S Economou
Journal:  J Immunol       Date:  2014-03-17       Impact factor: 5.422

8.  The selenium metabolite methylselenol regulates the expression of ligands that trigger immune activation through the lymphocyte receptor NKG2D.

Authors:  Michael Hagemann-Jensen; Franziska Uhlenbrock; Stephanie Kehlet; Lars Andresen; Charlotte Gabel-Jensen; Lars Ellgaard; Bente Gammelgaard; Søren Skov
Journal:  J Biol Chem       Date:  2014-09-25       Impact factor: 5.157

9.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

Review 10.  Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

Authors:  Eléonore Beurel; Suzanne M Michalek; Richard S Jope
Journal:  Trends Immunol       Date:  2009-10-14       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.